Synaptogenix, Inc. (SNPX)
NASDAQ: SNPX · Real-Time Price · USD
2.350
+0.051 (2.22%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Company Description
Synaptogenix, Inc. operates as a biopharmaceutical company.
The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage.
It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
The company was incorporated in 2012 and is headquartered in New York, New York.
Synaptogenix, Inc.
Country | United States |
Founded | 2012 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 4 |
CEO | Alan Tuchman |
Contact Details
Address: 1185 Avenue of the Americas, 3rd Floor New York, New York 10036 United States | |
Phone | 973 242 0005 |
Website | synaptogen.com |
Stock Details
Ticker Symbol | SNPX |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001571934 |
CUSIP Number | 87167T201 |
ISIN Number | US87167T2015 |
Employer ID | 46-1585656 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Alan J. Tuchman M.D., MBA(FAAN) | Chief Executive Officer and Director |
Dr. Daniel L. Alkon M.D. | President, Chief Scientific Officer and Director |
Robert Weinstein | Chief Financial Officer, Executive Vice President, Treasurer and Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2025 | 10-K | Annual Report |
Dec 20, 2024 | 8-K | Current Report |
Dec 6, 2024 | 8-K | Current Report |
Nov 20, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Nov 12, 2024 | 10-Q | Quarterly Report |
Nov 7, 2024 | DEF 14A | Other definitive proxy statements |
Nov 5, 2024 | ARS | Filing |
Oct 28, 2024 | PRE 14A | Other preliminary proxy statements |
Oct 21, 2024 | EFFECT | Notice of Effectiveness |
Oct 16, 2024 | UPLOAD | Filing |